YS2302018

YS2302018 is an investigational small molecule drug developed to treat dyslipidemia and cardiovascular diseases by targeting and disrupting lipoprotein(a) (Lp(a)) formation. Lp(a) is a form of low-density lipoprotein (LDL) that transports cholesterol in the bloodstream; elevated levels are a significant risk factor for coronary artery disease, stroke, and other cardiovascular conditions. Unlike current therapies that indirectly lower Lp(a), YS2302018 acts as a direct oral disruptor of Lp(a), offering the potential for once-daily oral dosing. The drug was discovered by CSPC Pharmaceutical Group and has been licensed exclusively to AstraZeneca for further development and commercialization. It remains in preclinical development but represents a novel approach within the lipid-lowering therapy landscape[1][3][4][6][7][8].